🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being described as a "significant breakthrough" in the fight against superbug strains of the bacteria, according to scientists.

An International Challenge

Gonorrhoea infections are increasing globally, with data suggesting more than 82 million new cases per year. Particularly high rates are observed in Africa and countries within the WHO's designated area, which includes Mongolia and China to New Zealand. Across England, cases have hit a historical peak, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary step in the reality of rising global incidence, the spread of superbugs and the extremely scarce therapeutic options presently on offer.”

Public health authorities are increasingly worried about the increase in drug-resistant strains. The World Health Organization has listed it as a "critical concern". A tracking program revealed that the effectiveness of primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Drugs Gain Authorization

Zoliflodacin, marketed under the name Nuzolvence, was cleared by the US Food and Drug Administration in December for use against gonorrhoea. This disease can lead to serious health problems, including infertility. Researchers hope that targeted use of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, gained clearance in close succession. This treatment, which is employed against UTIs, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin stemmed from a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to bring it to fruition.

“This authorization signifies a huge turning point in the treatment of superbug gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Testing Outcomes and Global Access

Based on findings released by a prominent scientific publication, the new drug successfully treated over nine in ten of genital gonorrhoea infections. This establishes an similar efficacy with the existing first-line therapy, which involves two antibiotics. The research involved hundreds of volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, GARDP has the authority to make available and distribute the drug in a wide range of developing nations.

Clinicians directly involved have shared positive views. Having a one-pill regimen of this kind is hailed as a "critical tool" for managing the epidemic. This is considered vital to lessen the impact of the infection for people and to stop the proliferation of untreatable gonorrhoea globally.